Insider Selling: Tempus AI (NASDAQ:TEM) EVP Sells 5,205 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 5,205 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $65.54, for a total value of $341,135.70. Following the completion of the transaction, the executive vice president owned 126,851 shares of the company’s stock, valued at approximately $8,313,814.54. This represents a 3.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, November 19th, Andrew Polovin sold 6,387 shares of Tempus AI stock. The stock was sold at an average price of $68.06, for a total transaction of $434,699.22.

Tempus AI Price Performance

NASDAQ:TEM traded down $3.40 during mid-day trading on Thursday, hitting $65.69. 7,149,431 shares of the company’s stock traded hands, compared to its average volume of 11,236,510. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. The firm’s 50 day simple moving average is $84.42 and its 200 day simple moving average is $71.91. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $104.32. The company has a market cap of $11.69 billion, a PE ratio of -55.20 and a beta of 4.86.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company had revenue of $334.21 million for the quarter, compared to the consensus estimate of $328.89 million. During the same quarter in the prior year, the firm earned ($0.46) earnings per share. The company’s revenue for the quarter was up 84.7% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. Sell-side analysts expect that Tempus AI, Inc. will post -6.15 EPS for the current year.

Institutional Investors Weigh In On Tempus AI

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its holdings in Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock valued at $894,000 after buying an additional 162 shares during the period. Global Retirement Partners LLC increased its position in shares of Tempus AI by 29.5% in the third quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock worth $59,000 after acquiring an additional 167 shares in the last quarter. US Bancorp DE raised its stake in shares of Tempus AI by 6.6% in the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company’s stock valued at $230,000 after acquiring an additional 176 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Tempus AI by 0.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 33,757 shares of the company’s stock valued at $2,145,000 after acquiring an additional 226 shares in the last quarter. Finally, SeaCrest Wealth Management LLC lifted its holdings in shares of Tempus AI by 3.7% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock valued at $524,000 after acquiring an additional 229 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. BTIG Research reissued a “buy” rating and set a $96.00 price target on shares of Tempus AI in a research report on Wednesday, November 5th. TD Cowen cut Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 price objective for the company. in a research report on Tuesday, October 21st. Cowen downgraded shares of Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Needham & Company LLC upped their target price on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Morgan Stanley lifted their price target on shares of Tempus AI from $68.00 to $80.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $80.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.